Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › OCGN

Ocugen

OCGN Rare disease Lead: Phase 3 ★ Read the deep dive → 13 Biotech Distilled articles ↓
Infectious DiseaseOphthalmology CellGene TherapyProtein

Most recent annual filing: 2026-03-04

Catalyst timeline

5 trackedQuarter catalyst calendar →
  1. OCU410ST Ph2/3 interim3Q 2026OCU410ST Ph2/3 interim, 3Q 2026, notable
  2. OCU410 Ph2 readoutlate 3Q 2026OCU410 Ph2 readout, late 3Q 2026, notable
  3. Reserved Share Proposal corporate updateSep 21, 2026Reserved Share Proposal corporate update, Sep 21, 2026, routine
  4. OCU400 Ph3 topline1Q 2027OCU400 Ph3 topline, 1Q 2027, thesis-defining
  5. OCU400 BLA filing1Q 2027OCU400 BLA filing, 1Q 2027, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (12 active programs)

Technology platforms

Novel Modifier Gene Therapy Platform · CanSino Biologics

Nuclear hormone receptor (NHR)-based modifier gene therapy platform using AAV5 vector delivery to retinal tissue; targets NR2E3 and RORA to address multiple inherited retinal diseases including retinitis pigmentosa, Stargardt disease, and dry AMD/geographic atrophy with a gene-agnostic approach

Targets: NR2E3, RORA

Inhaled Mucosal Vaccine Platform · Washington University in St. Louis

Next-generation inhalation-based mucosal vaccine platform based on a novel ChAd vector; designed to generate local mucosal immunity in the nasopharyngeal region for respiratory infectious diseases including COVID-19 and influenza

Targets: SARS-CoV-2 Spike protein, influenza

Biotech Distilled coverage (13)

Articles open on Substack. Some deep dives are subscriber-only.